Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues.

Buy your copy of this report @ http://www.reportsnreports.com/reports/190914-pharmaceutical-products-of-the-future-50-company-biopharma-and-traditional-pipeline-analysis-to-2016.html

Report Details:
Published: August 2012
No. of Pages: 220
Price:Single User License:US$2500 Corporate User License:US$5000



Coverage of the 50 Leading Companies


This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:
Abbott Laboratories
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen IDEC
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly & Co.
Forest
Gilead Sciences
GlaxoSmithKline
Grifols SA
Hospira
Johnson & Johnson
Kyowa Kirin
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Reckitt Benckiser
Roche
Sanofi
Santen Pharmaceuticals
Servier
Shionogi
Shire
Taisho Pharmacueitcal
Takeda
TEVA
UCB
Valeant Pharmaceuticals
Warner Chilcott
Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market Forecasts



This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
The Traditional Pharmaceutical Market
Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Issues and Trends discussed in this report include:
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry

Pharmacogenomic Partnering Terms and Agreements

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual pharmacogenomic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of pharmacogenomic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmacogenomic dealmaking since 2005, including details of average headline, upfront, milestone and royalty terms.

Pharmacogenomic Partnering Terms and Agreements Market

Published: February 2012
No. of Pages:538
Price: Single User License: US$ 2695                   Corporate User License: US$ 13475 

Pharmacogenomic Partnering Terms and Agreements includes:

• Trends in pharmacogenomic dealmaking in the biopharma industry since 2007
• Analysis of pharmacogenomic deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life pharmacogenomic deals
• Access to over 500 pharmacogenomic contract documents
• The leading pharmacogenomic deals by value since 2007
• Most active pharmacogenomic dealmakers since 2007
• The leading pharmacogenomic partnering resources

In Pharmacogenomic Partnering Terms and Agreements, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Pharmacogenomic Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of pharmacogenomic deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of pharmacogenomic agreements with numerous real life case studies
• Comprehensive access to over 500 actual pharmacogenomic contracts entered into by the world’s biopharma companies
• Detailed access to actual pharmacogenomic contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a pharmacogenomic agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies